Genenta Science Regains Nasdaq Compliance, Resolving Delisting Threat
GNTA has more than doubled off its 52-week low of $0.55 on light trading volume (0.2× avg).
Summary
Genenta Science S.p.A. announced it has regained compliance with Nasdaq's minimum bid price requirement, effectively resolving the delisting threat previously disclosed.
Key Events · Corporate Governance and Compliance · GNTA
-
Regained Nasdaq Compliance
Genenta Science S.p.A. received notification from Nasdaq that it has regained compliance with Listing Rule 5550(a)(2), which requires a minimum bid price of $1.00 per share.
-
Resolved Prior Deficiency
This action resolves the deficiency letter issued on April 14, 2026, which had notified the company of non-compliance due to its stock trading below $1.00 for 30 consecutive business days.
-
Sustained Bid Price
Nasdaq confirmed compliance after the company's American Depositary Shares (ADSs) maintained a closing bid price at or above $1.00 per share for 10 consecutive business days, from June 1 to June 12, 2026.
Analysis · GNTA · Life Sciences
This filing is important because it confirms Genenta Science has resolved the Nasdaq minimum bid price deficiency, removing the immediate threat of delisting. The company had previously received a deficiency letter on April 14, 2026, making this a critical positive development for investor confidence and the company's ability to remain publicly traded on Nasdaq.
How filings like this one have moved
In the 30 days to Oct 31, 2026, 39.9% of the 1148 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.36%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, GNTA was trading at $1.76 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $42.2M. The 52-week trading range was $0.55 to $10.00. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.